References
- American Diabetes Association. Standards of Medical Care in Diabetes – 2015. Diabetes Care 2015;38(1 Suppl):S1-S93
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015;21:438-47
- Edelman S, Pettus J. Challenges associated with insulin therapy in type 2 diabetes mellitus. Am J Med 2014;127(10 Suppl):S11-16
- Kramer H, Cao G, Dugas L, et al. Increasing BMI and waist circumference and prevalence of obesity among adults with type 2 diabetes: the National Health and Nutrition Examination Surveys. J Diabetes Complications 2010;24:368-74
- Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care 2015;38:1161–72
- Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014;384:2228-34
- Diamant M, Nauck MA, Shaginian R, et al. Glucagon-like petide 1 receptor agonist or bolus insulin with ptiized basl insulin in type 2 diabetes. Diabetes Care 2014;37:2763-73
- Valencia WM, Florez H. Pharmacological treatment of diabetes in older people. Diabetes Obes Metab 2014;16:1192-203
- Huetson P, Palmer JL, Levorsen A, et al. Cost-effectiveness of the once-daily glp-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. J Med Econ 2015:1-13 [ Epub ahead of print]
- Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin. Diabetes Care 2013;36:2489-96
- Liebl A, Khunti K, Orozo-Beltran D, et al. Health economic evaluation of type 2 diabetes mellitus: a clinical practice focused review. Clin Med Insights Endocrinol Diabetes 2015;8:13-19
- Valencia WM, Stoutenberg M, Florez H. Weight loss and physical activity for disease prevention in obese older adults: an important role for lifestyle management. Curr Diab Rep 2014;14:539-48
- McCabe C, Claxton K, Culyer AJ. The NICE cost-effectivness threshold: what it is and what that means. Pharmacoeconomics 2008;26:733-44
- Asche CV, Hippler SE, Eurich DT. Review of models used in economic analysis of new oral treatments for type 2 diabetes mellitus. PharmacoEconomics 2014;32:15-27
- Ngo-Metzger Q, Sorkin DH, Billimek J, et al. The effects of financial pressures on adherence and glucose control among racial/ethnically diverse patients with diabetes. J Gen Intern Med 2011;27:432-7
- Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301
- Su W, Huang J, Chen F, et al. Modeling the clinical and economic implications of obesity using microsimulation. J Med Econ 2015; Aug 13:1-12 [ Epub ahead of print]
- Khazrai YM, Buzzetti R, Del Prato S, et al. The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. J Diabetes Complications 2015;29:599-606